NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”) (NASDAQ: ACHN) stock prior to October 16, 2019.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Achillion to Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ: ALXN). Under the terms of the deal, shareholders of Achillion will receive $6.50 in cash, plus potential additional contingent considerations for each share of Achillion they own. To learn more about the action and your rights, go to:
The Achillion merger investigation concerns whether the Board of Achillion breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Alexion is underpaying for Achillion, thus unlawfully harming Achillion shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171